Pantoprazol +pharma (Pantoprazole Sodium Sesquihydrate)

Pantoprazole is a proton pump inhibitor that acts on the gastric acid secretion pathway. It is indicated for several acid‑related conditions:

• Gastro‑oesophageal reflux disease (GERD): provides relief of heartburn and promotes healing of the oesophageal lining.
• Erosive oesophagitis: accelerates endoscopic healing of erosive lesions.
• Peptic ulcer disease: supports ulcer healing and reduces risk of recurrence.
• Zollinger‑Ellison syndrome: controls gastric acid hypersecretion associated with this rare endocrine disorder.

• Pantoprazole binds selectively to the H+/K+‑ATPase enzyme (the gastric proton pump) on the secretory surface of parietal cells. By irreversibly inhibiting this pump, it blocks the final step of acid production, leading to a sustained reduction in gastric acidity and allowing mucosal healing.

Pantoprazole is generally well tolerated, but adverse reactions can occur.

Common Side Effects

• Headache: mild to moderate intensity.
• Diarrhoea: usually self‑limiting.
• Nausea: occasional and transient.
• Abdominal pain: mild discomfort.
• Flatulence: increased intestinal gas.
• Constipation: occasional bowel habit change.

Serious or Rare Side Effects

• Severe hypersensitivity: rash, angio‑edema, or anaphylaxis.
• Clostridioides difficile infection: persistent diarrhoea with abdominal cramping.
• Low magnesium (hypomagnesemia): muscle cramps, tremor, or cardiac arrhythmia.
• Acute interstitial nephritis: renal impairment with eosinophilia.
• Fracture risk: reduced bone mineral density with long‑term use.
• Liver enzyme elevation: hepatitis‑like picture in rare cases.

When prescribing Pantoprazole, clinicians should consider several safety aspects:

• Renal impairment: dose adjustment may be required in severe kidney disease.
• Hepatic impairment: monitor liver function in patients with existing liver disease.
• Long‑term therapy: assess need for periodic review to avoid unnecessary prolonged use.
• Osteoporosis risk: evaluate bone health in patients at high fracture risk.
• Drug interactions: review concomitant medications for potential CYP‑mediated effects.
• Store at ambient temperature: keep below 25°C, retain original packaging, and protect from moisture.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

• Antifungal agents (ketoconazole, itraconazole): reduced absorption due to higher gastric pH.
• HIV protease inhibitors (atazanavir, nelfinavir): decreased plasma concentrations.
• Clopidogrel: diminished antiplatelet effect, increasing cardiovascular risk.

Moderate Interactions (Monitor Closely)

• Warfarin: possible increase in INR, requiring closer coagulation monitoring.
• Digoxin: slight rise in serum levels, monitor for toxicity.
• Methotrexate (high dose): reduced renal clearance, monitor renal function and drug levels.